Autifony Therapeutics initiates a Phase I study of its novel Kv3 modulator for schizophrenia and hearing disorders

Autifony Therapeutics, a biotechnology company developing novel treatments for serious disorders of the central nervous system, announced that a First-in-Human, randomized, placebo controlled Phase I trial of AUT00201, a potent and selective modulator of Kv3 channels, is underway in the UK.

Kv3 channel dysfunctions have been implicated in a variety of CNS disorders. Autifony’s AUT00201 selectively modulates the function of Kv3 channels and restore normal neuronal function.

The trial has been suspended temporarily in response to the COVID-19 pandemic.

Read the press release here.

Read more about Autifony Therapeutics here.

Image by Gerd Altmann from Pixabay